|
|
Authorized COVID-19 Vaccines
This site collects existing COVID-19 vaccines that are authorized or authorized for public use in at least one country as of January 8, 2021. This list includes vaccines that have received Emergency Use Authorization by a regulatory agency.
Existing vaccines that are authorized for public use include:
- AZD1222
- Other names: ChAdOx1 nCoV19, Covishield
- Manufacturer: AstraZeneca, University of Oxford
- Countries where authorized: UK, India, Argentina
- Clinical trial ID:
- Phase III: NCT04516746 (protocol)
- Age subgroups: 18-64 years, 65 years and above
- Location: USA, Argentina, Chile, Colombia, Peru
- Phase III: NCT04540393
- Age subgroups: 18 years and above
- Location: Russia
- Phase III: NCT04536051
- Age subgroups: 18-55 years, 56-69 years, 70 years and above
- Location: Brazil
- Phase III: ISRCTN89951424
- Age subgroups: 18-55 years
- Location: Brazil
- Phase III: CTRI/2020/08/027170
- Age subgroups: 18 years and above
- Location: India
- Type: Recombinant vector vaccine
- Publications:
- Barrett et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2020; ; . [PubMed: 33335322].
- Ewer et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; ; . [PubMed: 33335323].
- Voysey et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; S0140-6736(20)32661-1. [PubMed: 33306989].
- Folegatti et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249); 467-478. [PubMed: 32702298].
- VIOLIN: 5774
- VO: VO_0005158
- BBIBP-CorV
- Manufacturer: Beijing Institute of Biological Products, Sinopharm
- Countries where authorized: China, Bahrain, United Arab Emirates
- Clinical trial ID:
- Phase III: NCT04560881
- Age subgroups: 18-85 years
- Location: Argentina
- Phase III: NCT04510207
- Age subgroups: 18 years and above
- Location: Bahrain, Egypt, Jordan, UAE
- Phase III: ChiCTR2000034780
- Age subgroups: Healthy adults aged 18 years and above
- Location: UAE
- Type: Inactivated or “killed” vaccine
- Publications:
- Wang et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3); 713-721. [PubMed: 32778225].
- VIOLIN: 5776
- VO: VO_0005166
- BNT162b2
- Other names: Comirnaty, Tozinameran
- Manufacturer: BioNTech, Pfizer
- Countries where authorized: USA, Canada, and other countries
- Clinical trial ID:
- Phase I/II/III: NCT04368728 (protocol)
- Age subgroups:
- Phase I: 18-55 years, 65-85 years
- Phase II/III: 12-15 years, 16-55 years, 56 years and above
- Location: USA, Argentina, Brazil, Germany, South Africa, Turkey
- Type: mRNA vaccine
- Publications:
- Polack et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27); 2603-2615. [PubMed: 33301246].
- Walsh et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; ; . [PubMed: 33053279].
- Sahin et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature. 2020; ; . [PubMed: 32998157].
- Mulligan et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; ; . [PubMed: 32785213].
- Additional links:
- VIOLIN: 5784
- VO: VO_0004987
- COVAXIN
- Other names: BBV152
- Manufacturer: Bharat Biotech
- Countries where authorized: India
- Clinical trial ID:
- Type: Inactivated or “killed” vaccine
- VIOLIN: 5795
- VO: VO_0004991
- Gam-COVID-Vac
- Other names: Sputnik V
- Manufacturer: Gamaleya Research Institute
- Countries where authorized: Russia
- Clinical trial ID:
- Phase III: NCT04530396
- Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 61 years and above
- Location: Russia
- Phase III: NCT04564716
- Age subgroups: 18-60 years
- Location: Belarus
- Phase III: NCT04642339
- Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 60 years and above
- Location: Venezuela
- Phase III: NCT04656613
- Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 60 years and above
- Type: Recombinant vector vaccine
- Publications:
- Logunov et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255); 887-897. [PubMed: 32896291].
- VIOLIN: 5777
- VO: VO_0005163
- mRNA-1273
- Manufacturer: Moderna
- Countries where authorized: USA, Canada, UK
- Clinical trial ID:
- Phase III: NCT04470427 (protocol)
- Age subgroups: 18-64 years, 65 years and above
- Location: USA
- Race/ethnicity:
- Asian: 4%
- Black/African American: 10%
- Hispanic/Latinx: 20%
- White: 63%
- All others: 3%
- Type: mRNA vaccine
- Publications:
- Baden et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; ; . [PubMed: 33378609].
- Anderson et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; ; . [PubMed: 32991794].
- Additional links:
- VIOLIN: 5789
- VO: VO_0005157
Provenance: All data in Cov19VaxKB originates from manual curation of reliable resources.
Note: The page was updated on January 8, 2021. We plan to update this page on a weekly or even a daily basis. Please provide us with any new information that you believe would be useful if included on the website.
|
